Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Australian health care's burnout prescription

"Fake podiatrist" jailed after hundreds of consultations with vulnerable patients

Unlocking the potential of our nursing workforce

National Model for Clinical Governance now available

SEKO IoT solutions revolutionise on-premise laundry dosing

Sydney next to welcome electric hydrofoiling vessels

Newcastle Airport receives 5 Star Green Star Buildings certification

COP31 electrification target announced

Councils named as best 'impossible-to-recycle' recyclers

New Qld expo focuses on waste and recycling

Larry Emdur's whisky brand appoints CEO

Fonterra's leadership changes confirmed

Driving food safety through digital traceability and transparency

Mars expands local pet food production with new $112.6m facility now open

New analytical method for testing gluten-free beer assessed